Despite demonstrating biological activity and a favorable safety profile, AOD9604 has not achieved regulatory approval as an obesity therapeutic
Background Almost half of adults worldwide now live with excess body fat, a figure projected to climb to 54% by 2035, and it drives type 2 diabetes, hypertension, dyslipidemia, osteoarthritis, and mood disorders
But with so many people already taking compounded versions of these medicationsand with such great reported success in many casesthis muddled and abrupt cessation has provoked its own health care crisis
[DOI] [PMC free article] [PubMed] [Google Scholar] 24.Rizvi AA, Janez A, Al Mahmeed W, et al
This fills the syringe with air